The CLSG/GCEL panel recommends that FLT3 mutation testing (ITD and TKD) be performed at the time of initial diagnosis in all untreated adult patients with:AML (de novo, secondary, or therapy-related);Acute leukemias of mixed or ambiguous lineage;Other acute leukemias if there are significant delays in the confirmation of phenotype/lineage. The gene discussed is FLT3; the disease is acute myeloid leukemia.